Protection rate was determined both at baseline and at endpoint.
A higher ISI at baseline conferred protection from a rapid decline of GFR as assessed by CKD-EPI cystatin C (0.77 [0.64–0.92], P = 0.004) and remained significant after adjusting for HbA1c and age (0.80 [0.67–0.97], P = 0.02).
Importantly, at 2 years, nearly all participants reported daily routine practice of at least one sun-protection method, compared to 78.1% at baseline.
At baseline in 2002 only the aggregated variable 'good personal protection' showed a significant difference between the FFS farmers and neighbor farmers (χ-test, p < 0.05), see Table 1.
The secondary objectives will describe the interaction between bacteria and human host at baseline, through inoculation and symptomatic infection (or asymptomatic immune protection) to recovery and long-term follow-up (see table 1).
Multivariate profile analysis indicated that all 3 participant groups reported increased daily routine practice of sun-protection 2 years following melanoma genetic testing (p<.02), with 96.9% reporting that at least 1 sun-protection behavior was part of their daily routine, up from 78.1% at baseline (p<.015).
The similarity of hormone users and non-users at baseline and the consistency of effect with different model formulations offers some protection against this.
Our results are consistent with the hypothesis that brain regions with relative protection from AD pathology will also tend to show a less abnormal gene expression signature at baseline.
At baseline and 2 years, participants rated the extent to which each sun-protection behavior (sunscreen, photoprotective clothing, UVR avoidance) was part of their daily routine (1=not at all; 5=very much).
Social cognitive variables related to physical activity behaviors from protection motivation theory, theory of planned behaviour, social cognitive theory, and stages of change will also be examined at baseline, 3 and 6 months using validated measures [ 41].
Dual protection (use of condom and another FP method) was significantly higher among HIV-positive than HIV-negative women at baseline (41 vs. 3 %; p < 0.001) and endline (87 vs. 8 %; p < 0.001), and increased dramatically over the two-year period; among HIV-negative women there was also a significant increase in the proportion reporting dual protection (Table 3).
